Investments, Funding & Disinvestment

The company has launched Invenia Automated Breast Ultrasound (ABUS) Prime and ABUS StreamVue, which target different stages of the breast imaging workflow.

The Phase 1 study forms part of an expanded collaboration between Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI).

Under the definitive agreement, KKR will acquire all outstanding shares of Integer Holdings for US$127 per share in cash.

The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.

The partnership will support Nigeria’s post-marketing vaccine surveillance system by evaluating innovative screening devices and expanding routine laboratory testing for vaccine lots.

CereVasc designed the facility to meet the company’s expected operational needs as it advances the eShunt System towards potential commercialisation.

The divestment forms part of the company’s broader restructuring as it seeks to strengthen its finances and sharpen its focus on higher-value healthcare products.

IMPACT Therapeutics received approval from China’s National Medical Products Administration (NMPA) in January 2025 for senaparib as a first-line maintenance therapy for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer.

AbCellera will oversee discovery and early-stage development activities, while Vertex will finance all research and development costs.

BYPHAR is designed to simplify raw material selection while helping manufacturers meet increasingly stringent quality and regulatory requirements throughout the development and production process.